Sanofi Consumer Healthcare India: CFO Maithilee Mistry, Head of Commercial Operations Rupendra Sachdev to step down
Mumbai: Sanofi Consumer Healthcare India Limited has announced the upcoming departure of two of its senior leaders.
Maithilee Mistry, Whole-time Director and Chief Financial Officer, has resigned to explore new opportunities outside the organization.
"Her resignation will be effective from the end of business hours of May 5, 2025, which shall be her last working day with the Company," it informed in a BSE filing.
Maithilee Mistry, a qualified Chartered Accountant (CA), served as Global Funding Director at Dow Chemical Company, USA, where she managed corporate funding and banking relations. She has also served as a Board Member for multiple organizations, including a public-listed entity and joint ventures in India. Previously, she held leadership roles with Omya and Cognis, European multinational corporations, overseeing operations in India and Southwest Asia. She began her career with Deloitte (India) as part of the statutory audit team. Mistry holds a Bachelor of Commerce degree from Mumbai University, and has completed an executive program in strategic planning from Columbia Business School.
Read also: USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors
Additionally, Rupendra Sachdev, Head – Commercial Operations and a Senior Management Personnel, has also decided to step down from his current role to pursue his entrepreneurial aspirations and the same will be effective from the end of business hours of April 30, 2025, marking his last working day with the Company.
Read also: Sanofi gets USFDA fast track designation for Chlamydia vaccine candidate
Rupendra Sachdev has been associated with Sanofi group since February 14, 1990 and has been associated with the Company since June 1, 2024. He holds a post graduate certificate in business management from XLRI, Jamshedpur. He has over 30 years of experience in sales and marketing with more than 15 years of managing CHC brands.
Read also: USFDA grants orphan drug designation to Sanofi Rilzabrutinib for two rare diseases
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.